US 11,896,043 B2
Intestinal immune-enhancing agent, food product, and medicament
Tadashi Takeuchi, Wako (JP); Eiji Miyauchi, Wako (JP); Shu Shimamoto, Tokyo (JP); Akinobu Matsuyama, Tokyo (JP); and Hiroshi Ohno, Wako (JP)
Assigned to DAICEL CORPORATION, Osaka (JP)
Filed by DAICEL CORPORATION, Osaka (JP)
Filed on Sep. 15, 2021, as Appl. No. 17/476,131.
Application 17/476,131 is a continuation of application No. 16/759,074, abandoned, previously published as PCT/JP2018/039373, filed on Oct. 23, 2018.
Claims priority of application No. 2017-207154 (JP), filed on Oct. 26, 2017.
Prior Publication US 2022/0061372 A1, Mar. 3, 2022
Int. Cl. A23L 33/24 (2016.01); A61K 31/717 (2006.01); G06F 17/18 (2006.01)
CPC A23L 33/24 (2016.08) [A61K 31/717 (2013.01); G06F 17/18 (2013.01)] 5 Claims
 
1. A method for increasing and maintaining of IgA in the intestinal tract of a subject in need thereof, comprising
intaking by the subject or administering to the subject a cellulose acetate having a total degree of acetyl substitution from 0.4 to 1.1;
wherein an intake or administration dose per serving is from 5 mg/kg body weight to 60 mg/kg body weight.